Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Youssef Josephson

Interventional Pain Medicine West Deptford, NJ Doctor of Osteopathy

NPI 1598928608 CMS profile 72476

196 Grove Ave Ste E, West Deptford, NJ 08086

Open in the dashboard

General payments

$496,336

2,051 records reported · program years 2019–2025

Research payments

$855

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$85,578 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Youssef Josephson of West Deptford, NJ is reported in the CMS Open Payments database as having received $496,336 across 2,051 general payments and $855 in research payments paid to them. Separately, studies naming them as principal investigator received $85,578 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,510 166
2024 General $33,400 186
2023 General $29,352 208
2023 Research $475 1
2022 General $61,226 349
2021 General $90,240 349
2021 Research $380 2
2020 General $99,581 297
2019 General $163,027 496

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Youssef Josephson
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Youssef Josephson were reported at $19,510. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Youssef Josephson Interventional Pain Medicine median Middle half National median
2019 $163,027 $684 $216–$2,079 $163
2020 $99,581 $382 $122–$1,109 $114
2021 $90,240 $552 $167–$1,554 $132
2022 $61,226 $605 $187–$1,924 $149
2023 $29,352 $671 $195–$1,915 $160
2024 $33,400 $684 $206–$1,837 $164
2025 $19,510 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $172,929 705 payments
  2. Boston Scientific Corporation $121,169 233 payments
  3. Vertiflex, Inc. $98,432 126 payments
  4. Medtronic USA, Inc. $37,177 117 payments
  5. Painteq LLC $22,357 107 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $8,373 81 payments
  7. TerSera Therapeutics LLC $7,397 41 payments
  8. Medtronic, Inc. $7,289 45 payments
  9. Aurora Spine, Inc. $5,280 3 payments
  10. Vertos Medical, Inc. $4,557 39 payments
  11. Other $11,375 554 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $243,881 76 payments
  2. Consulting Fee $88,037 50 payments
  3. Travel and Lodging $51,512 161 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $44,779 32 payments
  5. Food and Beverage $40,637 1,711 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $21,031 12 payments
  7. Education $6,312 5 payments
  8. Entertainment $147 4 payments
Products named General payments · program years 2019–2025
  1. Superion ISS $98,432 126 payments
  2. Superion Pain Management $60,427 24 payments
  3. PROCLAIM Neuromodulation $42,977 67 payments
  4. Neuromodulation Dspsbls and Accs $41,181 34 payments
  5. PROCLAIM Neuromodulation $39,469 239 payments
  6. VERIFLEX $25,413 6 payments
  7. SUPERION Pain Management $22,511 14 payments
  8. PAINTEQ $22,357 107 payments
  9. SYNCHROMED $13,750 2 payments
  10. Proclaim Family of SCS IPGs $11,207 105 payments
  11. Other $118,170 1,509 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Painteq LLC $625 2 payments
  2. Medtronic, Inc. $230 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

2,505

Median for Pain Management: 951

Drug cost

$86,485

Median for Pain Management: $26,034

Branded share of claims

24.5%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 36 $19,482
Belbuca Buprenorphine Hcl Brand 27 $18,341
Morphine Sulfate Er Morphine Sulfate Brand 73 $6,288
Oxycodone Hcl Generic 282 $6,158
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 269 $5,516
Gabapentin Generic 322 $4,598
Fentanyl Generic 52 $4,305
Lidocaine Generic 38 $4,049
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 196 $3,980
Celecoxib Generic 102 $2,604

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$366,273

Of which drugs: $4,844

Medicare patients

494

Average age 70

Services billed

5,464

306 women, 188 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 33%
Diabetes 32%
Ischemic heart disease 31%
COPD 24%
Chronic kidney disease 21%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 35 740 $67

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Prialt
$142 — —
XTAMPZA
$98 — —
BELBUCA
$80 27 —
ROXYBOND
$45 — —
RELISTOR
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

2,054 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record